This Leading Healthcare Company s New Obesity Treatment Has Great Potential fool.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fool.com Daily Mail and Mail on Sunday newspapers.
Late last Friday, the U.S. Food and Drug Administration approved a breakthrough weight-loss drug made by Danish company Novo Nordisk. As soon as later this month, the company plans to launch the drug, called Wegovy.
Wegovy – a semaglutide 2.4 mg injection administered once a week – is specifically for chronic weight management in overweight or obese adults with "at least one weight-related comorbidity," according to pharmaceutical company Novo Nordisk.
The U.S. Food and Drug Administration (FDA) has approved Wegovy (semaglutide) injection (2.4 mg once weekly) as a chronic weight management treatment in obese or overweight adults with a weight-related condition (such as high blood pressure, type 2 diabetes, or high cholesterol), when used along with calorie restriction and physical activity. Wegovy, is a more potent version of Novo Nordisk's diabetes drug semaglutide.